恶名声
发表于 2025-3-28 16:43:19
http://reply.papertrans.cn/88/8773/877229/877229_41.png
猜忌
发表于 2025-3-28 22:15:49
http://reply.papertrans.cn/88/8773/877229/877229_42.png
招募
发表于 2025-3-29 01:34:11
Immune Reconstitution After Allogeneic Transplantatione system or genetic disorders, and even solid tumors. A11oHSCT allows marrow lethal treatment of the primary disorder as well as providing immunotherapy in the form of a graft-vs-tumor (GVT) effect. Despite more than 30 yr of experience with HSCT, the major barriers to this treatment have remained t
ABOUT
发表于 2025-3-29 03:07:37
http://reply.papertrans.cn/88/8773/877229/877229_44.png
进入
发表于 2025-3-29 09:16:51
http://reply.papertrans.cn/88/8773/877229/877229_45.png
革新
发表于 2025-3-29 13:41:59
Pathophysiology of Lung Injury After Hematopoietic Stem Cell Transplantationand nonmalignant conditions. Unfortunately, the utility of this treatment strategy is limited by several side effects, the most serious of which include the development of graft-vs-host disease (GVHD) and pulmonary toxicity. Pulmonary dysfunction, specifically diffuse lung injury, is a major complic
高度表
发表于 2025-3-29 16:39:48
http://reply.papertrans.cn/88/8773/877229/877229_47.png
匍匐前进
发表于 2025-3-29 21:36:00
Quality-of-Life Issues Posttransplantationemotional status, and spiritual/existential qualities. It reflects how well people feel, what they can accomplish, how satisfied they are with their lives, and whether their lives have meaning and purpose. Within this broad concept, health-related quality of life (HR-QOL) refers to aspects of QOL th
排名真古怪
发表于 2025-3-30 03:54:45
Stem Cell SourcesSCT) has been both a scientifically enlightening and a clinically useful observation in SCT technology. Over the past decade, our understanding of peripheral blood stem cell (PB SC) properties has increased dramatically, and as a consequence, the use of PBSCs in autologous and allogeneic transplanta
才能
发表于 2025-3-30 07:41:18
Allogeneic Unrelated Donor Blood and Marrow Transplantation immunodeficiencies, hemoglobinopathies, and inherited metabolic diseases . Unfortunately, only approx 25–30% of patients will have a suitable human leukocyte antigen (HLA) genotypically identical sibling donor available to facilitate transplant therapy. An extensive family search may find a closely